[Ischemic preconditioning. Does this animal experiment phenomenon have clinical relevance?]

Area of Science:

• Cardiology
• Cardioprotection
• Ischemic Preconditioning

Context:

• Ischemic preconditioning significantly reduces infarct size in animal models.
• Evidence suggests preconditioning effects are also present in humans, observed during angina and coronary angioplasty.
• Pharmacological agents mimicking preconditioning are being investigated for cardioprotection.

Purpose:

• To review the evidence for ischemic preconditioning in humans.
• To discuss pharmacological agents with preconditioning-like effects.
• To explore therapeutic implications and potential anti-preconditioning effects in clinical settings.

Summary:

• Ischemic preconditioning, a phenomenon reducing heart damage from ischemia, is observed in humans through angina and angioplasty.
• Pharmacological agents like adenosine and nicorandil demonstrate cardioprotective effects, similar to ischemic preconditioning.
• Therapeutic strategies involve preconditioning before procedures, but potential anti-preconditioning effects of drugs like glibenclamide require careful consideration.

Impact:

• Highlights the potential of ischemic preconditioning and pharmacological preconditioning for cardioprotection in clinical practice.
• Emphasizes the need for careful drug selection to avoid anti-preconditioning effects, particularly in patients with coronary artery disease.
• Calls for further clinical studies to bridge the gap between laboratory findings and evidence-based medical applications for ischemic preconditioning.